Literature DB >> 18230611

CaV3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells.

Florian Gackière1, Gabriel Bidaux, Philippe Delcourt, Fabien Van Coppenolle, Maria Katsogiannou, Etienne Dewailly, Alexis Bavencoffe, Myriam Tran Van Chuoï-Mariot, Brigitte Mauroy, Natalia Prevarskaya, Pascal Mariot.   

Abstract

Because prostate cancer is, in its early stages, an androgen-dependent pathology, treatments aiming at decreasing testosterone plasma concentration have been developed for many years now. However, a significant proportion of patients suffer a relapse after a few years of hormone therapy. The androgen-independent stage of prostate cancer has been shown to be associated with the development of neuroendocrine differentiation. We previously demonstrated that neuroendocrine prostate cancer cells derived from LNCaP cells overexpress CaV3.2 T-type voltage-dependent calcium channels. We demonstrate here using prostatic acid phosphatase as a marker of prostate secretion and FM1-43 fluorescence imaging of membrane trafficking that neuroendocrine differentiation is associated with an increase in calcium-dependent secretion which critically relies on CaV3.2 T-type calcium channel activity. In addition, we show that these channels are expressed by neuroendocrine cells in prostate cancer tissues obtained from patients after surgery. We propose that CaV3.2 T-type calcium channel up-regulation may account for the alteration of secretion during prostate cancer development and that these channels, by promoting the secretion of potential mitogenic factors, could participate in the progression of the disease toward an androgen-independent stage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230611     DOI: 10.1074/jbc.M707159200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.

Authors:  Megan Hall; Bryan Todd; Edwin D Allen; Nga Nguyen; Yoon-Jung Kwon; Vu Nguyen; Jennifer L Hearne; Miguel Martin-Caraballo
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 2.  Recent advances in the development of T-type calcium channel blockers for pain intervention.

Authors:  Terrance P Snutch; Gerald W Zamponi
Journal:  Br J Pharmacol       Date:  2017-07-12       Impact factor: 8.739

Review 3.  Calcium channels and pumps in cancer: changes and consequences.

Authors:  Gregory R Monteith; Felicity M Davis; Sarah J Roberts-Thomson
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 4.  T-type Ca2+ channels and the urinary and male genital tracts.

Authors:  C H Fry; R I Jabr
Journal:  Pflugers Arch       Date:  2014-01-25       Impact factor: 3.657

Review 5.  T-type channel-mediated neurotransmitter release.

Authors:  Emilio Carbone; Chiara Calorio; David H F Vandael
Journal:  Pflugers Arch       Date:  2014-03-06       Impact factor: 3.657

Review 6.  Modulation of T-type calcium channels by bioactive lipids.

Authors:  Jean Chemin; Magali Cazade; Philippe Lory
Journal:  Pflugers Arch       Date:  2014-02-16       Impact factor: 3.657

Review 7.  T-type calcium channels blockers as new tools in cancer therapies.

Authors:  Barbara Dziegielewska; Lloyd S Gray; Jaroslaw Dziegielewski
Journal:  Pflugers Arch       Date:  2014-01-22       Impact factor: 3.657

8.  Fractal analysis and ionic dependence of endocytotic membrane activity of human breast cancer cells.

Authors:  Monika Krasowska; Zbigniew J Grzywna; Maria E Mycielska; Mustafa B A Djamgoz
Journal:  Eur Biophys J       Date:  2009-07-18       Impact factor: 1.733

Review 9.  T-type calcium channels in chronic pain: mouse models and specific blockers.

Authors:  Amaury François; Sophie Laffray; Anne Pizzoccaro; Alain Eschalier; Emmanuel Bourinet
Journal:  Pflugers Arch       Date:  2014-03-04       Impact factor: 3.657

10.  Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells.

Authors:  Maria Katsogiannou; Charbel El Boustany; Florian Gackiere; Philippe Delcourt; Anne Athias; Pascal Mariot; Etienne Dewailly; Nathalie Jouy; Christophe Lamaze; Gabriel Bidaux; Brigitte Mauroy; Natalia Prevarskaya; Christian Slomianny
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.